Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

elasomeran

A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of SARS-CoV-2, with potential immunizing activity against SARS-CoV-2. Upon administration of elasomeran, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:lipid nanoparticle-encapsulated mRNA-based SARS-CoV-2 vaccine mRNA-1273
LNP-encapsulated mRNA-based SARS-CoV-2 vaccine mRNA-1273
Moderna COVID-19 vaccine
Foreign brand name:Spikevax
Code name:CX-024414
M-1273
mRNA 1273
mRNA-1273
mRNA1273
TAK-919
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search